Companies Cryptocurrencies
Sesen Bio Inc
Sesen Bio Inc
Exchange: NasdaqGS
IPO Date: 06/02/2014
CEO: Mr. Thomas Cannell
Biotechnology Healthcare 🔗
  • SESN
  • 0.4482
  • 89399760
    market cap
  • 0.03419998
If you bought

shares of Sesen Bio Inc (SESN) on
You would have made
Old Price $12 Current Price $12

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The firm is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). The company targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.

Address: 245 1st St Ste 1800 Cambridge MASSACHUSETTS 02142

Stay updated.